

# Innovations for Tomorrow: The Must-Attend InvestorTalk Series of August 2023

written by Tracy Weslosky | August 11, 2023

As we catapult into a future shaped by quantum cybersecurity, green hydrogen, and state-of-the-art EV battery technology, the next week's InvestorTalk events stand as your passport to the bleeding edge of innovation. Set your calendars; these sessions are brimming with insights and revelations.

**Quantum eMotion Corp.** (TSXV: QNC | OTCQB: QNCCF): On August 15, delve deep into the fabric of quantum mechanics with Francis Bellido. As cyber threats evolve, Quantum eMotion is ensuring our digital fortresses stand impregnable. Their patented Quantum Random Number Generator capitalizes on quantum unpredictability, heralding a new dawn in hardware security. Targets? Everything from Blockchain to Quantum Cryptography.

[Click Here to Register for this InvestorTalk](#) at 9 AM EST.

**SunHydrogen, Inc.** (OTC: HYSR): Imagine powering tomorrow with sunlight and water. On August 16, Tim Young introduces us to the SunHydrogen Panel technology. With an ambition to fuel the emerging \$12 trillion hydrogen economy, SunHydrogen aims to drive the future – emission-free.

[Click Here to Register for this InvestorTalk](#) at 9 AM EST.

**Nano One Materials Corp.** (TSX: NANO): That same day, at 4 PM EST, Dan Blondal unveils the green magic behind efficient lithium-ion battery cathode materials. With giants like BASF and Rio Tinto as allies, Nano One's technology eyes the vast expanse of electric vehicles, energy storage, and consumer electronics

[Click Here to Register for this InvestorTalk](#)

**The Grand InvestorTalk at The National Club:** August 17 is an ensemble of visionaries:

- **Spencer Huh** from [\*NEO Battery Materials Ltd.\*](#) (TSXV: NBM | OTCQB: NBMFF): Unearthing the potentials of silicon in EV lithium-ion batteries.
- **Bundeep Singh Rangar** of [\*Fineqia International Inc.\*](#) (CSE: FNQ): Navigating the future web with digital assets, tokenization, and more.
- **Stephen Burega** from [\*Romios Gold Resources Inc.\*](#) (TSXV: RG | OTCQB: RMI0F): From precious metals in the “Golden Triangle” of BC to global mineral explorations – it’s a golden journey.
- **Thomas Smeenk** of [\*Hemostemix Inc.\*](#) (TSXV: HEM | OTCQB: HMTXF): Introducing blood-based stem cell therapeutics that have the potential to revolutionize healthcare.

**RSVP** for this event that kicks off at 9:30 AM EST by sending an email to [tracy@investornews.com](mailto:tracy@investornews.com)

### **Diving Deeper:**

*NEO Battery Materials Ltd.:* Based in Vancouver, they’re redefining EV battery materials, particularly silicon anode materials, promising enhanced efficiency and capacity over traditional graphite anodes.

*Romios Gold Resources Inc.:* This Canadian mineral giant, with its vast claims spanning from BC’s “Golden Triangle” to Nevada, merges tradition with innovation in gold, copper, and silver explorations.

*Hemostemix:* A pioneer in autologous stem cell therapy since 2003, this World Economic Forum Technology Pioneer Award winner is scaling blood-based stem cell therapeutics, which promise

groundbreaking treatments.

*Fineqia*: At the crossroads of the digital revolution, Fineqia is capitalizing on tokenization, blockchain tech, NFTs, AI, and fintech. From managing debt securities in the UK to investing in next-gen Internet technologies, they're forging digital frontiers.

Prepare for a week of revelations and insights. Whether you're a seasoned investor, an innovation enthusiast, or someone curious about tomorrow, next week's InvestorTalks is a trove of enlightenment. Mark your schedule and be part of this journey into the future.

---

## **Dr. McNorgan Discusses Hemostemix's Stem Cell Technology and Potential with Elon Musk's Neuralink**

written by InvestorNews | August 11, 2023

In this InvestorIntel interview, Tracy Weslosky talks with [Hemostemix Inc.](#)'s (TSXV: HEM | OTCQB: HMTXF) Advisory Board Member Dr. Chris McNorgan, Ph.D. about why Hemostemix's NCP-01 (Neural Cellular Precursors) technology would be of interest to a company like [Neuralink](#).

With Elon Musk's brain implant company Neuralink recently [receiving FDA approval](#) for human trials, Dr. McNorgan explains how NCP-01 can potentially assist in all phases of the

implantation process, including mitigating complications and ensuring proper functionality of the brain implants.

Neurons do not naturally regenerate, causing lifelong problems when damaged. With the potential to regenerate neuronal cells, Dr. McNorgan discusses how Hemostemix's NCP-01 technology can also help restore brain functionality in patients suffering from progressive dementia.

[Dr. McNorgan](#) directs the Computational Cognitive Neuroscience (CCN) laboratory at the University of Buffalo. His research focuses on computational cognitive neuroscience, developing computer models to simulate how the brain functions, and is directly relatable to neural electrode-based implantation.

Dr. McNorgan estimates the current market for assistive technologies related to brain signal interception and decoding is estimated to be around \$36.5 billion, but the potential market is much larger once the technology is perfected.

The applications of Hemostemix's technology extend beyond assistive technologies, including addressing conditions like blindness, hearing loss, and dementia.

To access the full InvestorIntel interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#)

## About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursors,

and cardiomyocyte cell precursors. The Company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in FDA Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. Its second product is NCP-01, used to help rebuild neuronal pathways in the brain after injury or disease.

To learn more about Hemostemix Inc., [click here](#)

***Disclaimer:*** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as

assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

# **Thomas Smeenck Discusses the Intersection of Hemostemix's NCP Treatment and Elon Musk's Neuralink**

written by InvestorNews | August 11, 2023

With Dr. McNorgan's appointment, it brings another expert onto the team that includes Dr. Henderson, a neurosurgeon, and Dr. Inna Sorel, the mother of the invention of NCP itself, to help drive the legitimacy of licensing the NCP-01 platform. Thomas discusses the potential for licensing and partnerships to take NCP-01 to the neural electrode-based implantation market, an industry that is being led by players such as Elon Musk's Neuralink.

---

# Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals

written by InvestorNews | August 11, 2023

[Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for the treatment of ischemic (lack of blood flow) disease and several other diseases including cardiomyopathy (heart tissue disease) and neuropathy (nerve cell disease). Hemostemix’s initial goal is to treat heart attack (ischemic heart disease) and various ischemic conditions such as ischemic limb disease.

**Hemostemix’s Product Platform (targets to repair) – ACP-01 (blood vessel cells), NCP-01 (nerve cells), CCP-01 (heart cells)**

# The Hemostemix Platform

ACP  
-01

NCP-  
01

CCP-  
01

Angiogenic Cell Precursor

Neovascularization at the site of need (ischemia)

Angina, Dilated and Ischemic Cardiomyopathy, Congestive Heart Failure

Neuronal Cell Precursor

Rebuilds neuronal pathways

Homes to site of injury

Small animal study of motor function and pain at Clemson Univ.

Cardiomyocyte Cell Precursor

Rebuilds Heart following Infarct

Mate with bioscaffold and complete a Small animal study in '23

5

Source: [Hemostemix company presentation](#)

Hemostemix's leading product is called ACP-01. It refers to Hemostemix's first stem cell treatment called angiogenic cell precursor ("ACP") one ("01"). The [ACP technology](#) uses a patient's own stem cells to treat that patient's disease by extracting the stem cells, growing the number of cells within 7 days, then using them to treat the patient with their own harvested stem cells. [According to](#) Hemostemix: "ACP-01 has been used as a treatment of 500 subjects, studied in including clinical trials, and are demonstrated to be completely safe and effective as a treatment of Angina, Dilated and Ischemic Cardiomyopathy, Peripheral Arterial Disease and Critical Limb Ischemia."



# Hemostemix plans to increase production of their ACP stem cell therapy for ischaemic disease

In some recent news [announced](#) in January this year, Hemostemix has ramped up their team in order to increase the production of ACP-01. Hemostemix President and CEO, Thomas Smeenk, [stated](#): *"Adding four employees to our team enables Hemostemix to produce up to 20 ACP treatments per month for clinical trials and compassionate treatments approved by regulators.....We expect up to 174 revenue production slots for the first full year of production. To fill them and balance our production schedule, we are working on a forward sales plan."*

A "sales plan" suggests that the commercialization of ACP is potentially in the near term.

In a recent [InvestorIntel CEO video](#), Thomas Smeenk revealed more about Hemostemix's master plan. He said Hemostemix's goal is to scale up production of ACP to "4,000 or more batches per month" and "the numbers are very significant, at \$25,000 per treatment...\$30,000 per treatment....the numbers get very large very fast".

**Hemostemix's scalable production plans over a 60-month period**

# Scalable Production

A Stepped Approach to Automated Scaled Production and Profitability

STEP 1	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6
MANUAL			SEMI-AUTO		FULLY AUTOMATED
20 batches/mo.	40 batches/mo.	60 batches/mo.	72 batches/mo.	80 batches/mo.	4000 batches/mo.
1 Team 1 Shift	2 Teams 2 Shifts	2 Teams 2 Shifts	2 Teams 2 Shifts	2 Teams 2 Shifts	5 facilities   10 employees/ facility   2 Shifts
Treatment Price \$25k	Treatment Price \$25k	Treatment Price \$25k	Treatment Price \$25k	Treatment Price \$25k	Treatment Price \$7.5k - \$25k
Treatment Cost \$14k	Treatment Cost \$11k	Treatment Cost \$10k	Treatment Cost \$6k	Treatment Cost \$6k	Treatment Cost \$2.5k
Elapsed Time 16 months	Elapsed Time 20 months	Elapsed Time 24 months	Elapsed Time 36 months	Elapsed Time 48 months	Elapsed Time 60 months

Hemostemix's sales target is to reach \$360 million of risk-adjusted sales in 2027 (see below or [page 14](#)). Quite impressive given Hemostemix's current market cap is [C\\$16 million](#).

Hemostemix's sales target is to reach \$360 million of risk-adjusted sales in 2027


# Scalable Production

GROWTH DRIVER: Cost Effective Scaling of Autologous Lab Processes

Significant Growth By 2029 — **\$22B+** NRA Revenue Potential

A Phased Approach to  
High Volume Low Cost Production of ACP01

**\$22B+**  
Non-Risk Adjusted\*\*



Source: [Hemostemix company presentation](#)

## Is Hemostemix's stem cell therapy effective?

Hemostemix's ACP treatments have been successful to date. For example, in a 2019 Phase II CLI Trial with 12 randomized double-blind subjects, the results [included](#): *"Healing of ulcers and resolution of ischemic rest pain occurred in 10 of the 12 patients (83%). There were no clinically significant safety issues. Outcomes were maintained for up to 4.5 years....."*

You can see more results including pictures in a past InvestorIntel article [here](#).

## Closing remarks

Some risks apply and there is still work ahead for Hemostemix to implement its plan of action. At this stage, the Company has received [US FDA Clinical Trial approval](#) and further regulatory approvals may be necessary, as well as further funding to achieve the Company's goals.

The best companies develop effective products that both help society and fill a strong need. Tesla (NASDAQ: TSLA) is doing this with electric vehicles (EVs) and sustainable energy. Hemostemix is working towards becoming a leading biotech health company using stem cells to significantly help some of society's most common and severe diseases. They have already won the World Economic Forum Technology Pioneer Award, have proven their treatment efficacy in clinical trials, and have a highly qualified [management team](#) and [reputable advisors](#).

2023 could potentially be a breakout year for Hemostemix Inc.

---

# Thomas Smeenck provides an update on Hemostemix's ACP-01 stem cell treatment for heart disease

written by InvestorNews | August 11, 2023

Peter Clausi interviews [Hemostemix Inc.](#)'s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenck about an update on their stem cell therapeutics to treat heart diseases and critical limb ischemia. Providing an update on the production timeline for ACP-01, Thomas discusses how Hemostemix has strengthened its scientific advisory board.

Thomas talks about the [appointment](#) of Dr. Nadia Giannetti and Dr. Renzo Cecere, two of the world's top cardiovascular physicians and stem cell scientists, as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. He explains how the recent addition to its scientific advisory board is a significant validation of ACP-01 to be "a first-to-patient approved therapeutic to treat heart disease and critical limb ischemia amongst other diseases of ischemia."

To access the full InvestorIntel interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

## About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded

in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit [www.hemostemix.com](http://www.hemostemix.com).

To learn more about Hemostemix Inc., [click here](#).

***Disclaimer:*** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

## **Hemostemix adds depth and strength to its scientific bench on the road to commercialization**

written by InvestorNews | August 11, 2023

Since we last [covered Hemostemix](#) where they released the promising results of their retrospective study of heart disease and the phase II clinical trial results of ACP-01 as a treatment for critical limb ischemia, their team has been making serious moves.

You may recall that [Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF)

is developing new treatments to treat ischemic (restricted blood flow) diseases by collecting a patient's own cells from their blood and manufacturing a personalized regenerative therapy that can be administered to a patient within 7 days. The efficient, scalable, and cost-effective platform has the potential to generate therapies for a broad range of ischemic diseases.

In a quartet of recent press releases, Hemostemix announced the addition of four new distinguished members to its Scientific Advisory Board – Dr. Terry Hébert, Ph.D., Dr. Nadia Giannetti, MD, Dr. Johannes Grillari, and Dr. Renzo Cecere, MD, FRCSC. They are all internationally recognized experts in their respective fields with a wealth of experience in cardiovascular care, clinical research, and drug development.

Through his research, [Dr. Hébert](#) strives to improve our understanding of G protein-coupled receptor (GPCR) and G protein signaling architectures to enhance drug discovery for heart disease and other serious diseases. Dr. Hébert's expertise will be a valuable asset to the Hemostemix team as they continue to work to develop innovative treatments for patients with cardiovascular disease.

[Dr. Giannetti](#) is a highly respected researcher and physician who has worked with more than 1000 patients with heart failure. She is a clinical researcher interested in improving care and outcomes for patients with heart failure and dilated cardiomyopathy. She is also the co-principal investigator of a large initiative looking at the role of stem cells in personalized therapy for cardiomyopathy, making her an excellent addition to Hemostemix's Scientific Advisory Board.

[Dr. Grillari](#) is a renowned expert on cellular aging and tissue regeneration, with over 20 years of research experience in the field. His appointment will bring a wealth of knowledge and



expertise to the Hemostemix team and will help to further their understanding of the molecular and physiological changes that occur during cell aging. His contributions will be invaluable in helping their team to achieve their goal of improving heart disease patient outcomes.

[Dr. Cecere](#) is an expert in the field of stem cell research and has been investigating novel methods to strengthen the stem-cell-induced regeneration of infarcted heart tissue for over a decade. In fact, Dr. Cecere's recent publication—systematic review and meta-analysis—demonstrates that stem cells, along with bioactive scaffolds, provide enhanced tissue regeneration in animal models of myocardial infarction (MI) compared to stem cells injected alone. His study gives more backing to the theory that ACP-01 bioactive scaffolds improve stem cell-induced repair after a patient suffers a MI.

The new Scientific Advisory Board members' experience should greatly assist in advancing to their phase II clinical trial, a step towards the goal of bringing ACP-01 to market and potentially improving the lives of heart failure patients around the world.

Hemostemix is also poised to gain more value from its NCP-01, which are autologous neuronal cell precursors. These precursors have the potential to treat the central and peripheral nervous systems. Hemostemix has announced [Mr. Thomas Abraham](#) has been appointed as President of PreCerv Inc., a wholly owned [subsidiary of Hemostemix](#). PreCerv has obtained a global field of use license to NCP-01 and its autologous stem cell technologies from Hemostemix. This license will allow PreCerv to fund its studies to unlock NCP's value for the shareholders of Hemostemix. Mr. Abraham is a highly accomplished business professional with more than 25 years of experience in financing, business development, governance, and risk management. He will



be responsible for financing and leading the team that studies, develops, and commercializes NCP-01 and ACP-01 in the neuronal field, and bringing them to market for the benefit of patients suffering from neurological diseases.

Success for a public company often owes a lot to the team and talent it assembles, especially in the field of biotech and therapeutics. With these additions, Hemostemix has taken a big step toward advancing its suite of products in development.

---

## **Hemostemix posts promising clinical trial results from heart failure and limb ischemia treatment**

written by InvestorNews | August 11, 2023

Heart failure (HF) is a growing epidemic in the United States, with an estimated [6 million people](#) affected. HF is a debilitating condition that can significantly reduce patient quality of life and, in severe cases, prove fatal. Within five years of hospitalization, the [death rate](#) for HF patients ranges from 45% to 60%. Given the high mortality rate and the significant impact on quality of life, there is a great need for effective treatments for HF.

Stem cell therapy has been touted as a revolutionary medical treatment for a variety of conditions for some time. Stem cells have a number of properties, including paracrine and anti-

inflammatory effects, that are potentially useful for conditions where conventional medical treatments do not lead to enough optimal patient outcomes.

Acute cardiac progenitor cells (ACP-01) have emerged as a promising therapeutic option for HF. These cells have the ability to replace damaged cells, stimulate new blood vessel growth, and reduce inflammation. One company, in particular, has been working for years to develop and commercialize these cells in new treatments.

[Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF) is developing new treatments to treat ischemic (restricted blood flow) diseases. Hemostemix's technology uses a patient's own cells, collected through a simple blood draw, to treat that patient's disease. Its proprietary technology collects synergetic cell population and manufactures a personalized regenerative therapy that can be administered to a patient within 7 days of the initial cell collection. The efficient, scalable, and cost-effective platform has the potential to generate therapies for a broad range of ischemic diseases.

On August 30th, 2022, [Hemostemix announced](#) the results of their retrospective study of heart disease and the phase II clinical trial results of ACP-01 as a treatment for critical limb ischemia.

In the heart disease study, patients received a direct injection into the heart, or a balloon angioplasty-like release of ACP-01 into the heart's vasculature to address either hardening of the arteries (ischemic cardiomyopathy), or thickening of the heart wall (dilated cardiomyopathy).

The study showed that ACP-01 positively affects cardiac function in patients with both types of severe heart failure. The researchers measured cardiac function in terms of the volume of

blood the heart pumps with each beat, the ejection fraction of the left ventricle (LVEF%) before and after ACP treatment at an average of 4 and 12 months. It was found that the LVEF% was increased by 16.08% in all patients at first follow-up and by 26.88% on final follow-up. These results suggest that ACP-01 may be a viable treatment option for patients with severe heart failure.

The results of ACP-01 treatment for critical limb ischemia showed that ACP-01 was safe, trended to improve the healing of ulcers at 3, 6, and 12 months, and trended to a reduction in pain at 12 months. In a previous randomized trial of 20 subjects, after 2 years there were no deaths and 7 of 10 limbs were saved from amputation, compared to the control group where 2 patients died and 6 of 8 limbs were lost to amputation. Hemostemix's [press release](#) noted that its previous management team truncated the trial to 65 subjects, which effected the power of the study. The overall encouraging results of these studies showcase the need for further clinical trials of ACP-01.

Thomas Smeenck, CEO of Hemostemix, commented in the press release that the results show ACP-01 is safe and statistically effective as a treatment of heart disease, safe as a treatment of critical limb ischemia, and worthy of additional clinical trials. "Proving the efficacy of ACP-01 in prospective, blinded, randomized clinical trial, to gain regulatory approval is next," he said.

Hemostemix has said that its next move is to go "forward with a phase II clinical trial of heart disease financed, ideally, through a partnership." Clinical trials [can be expensive](#), and it is not uncommon for smaller biotechnology companies to partner with larger companies or pharmaceutical giants to fund their way through different levels of trials to regulatory approval, provided early results are promising. Hemostemix's results could

well attract the right kind of attention.

---

# Thomas Smeenck of Hemostemix talks about market reaction to successful litigation settlement

written by InvestorNews | August 11, 2023

In this InvestorIntel interview with host Stephen Lautens, [Hemostemix Inc.](#)'s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenck talks about Hemostemix achieving a major [milestone](#) this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market's immediate positive reaction.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel ([click here](#)), Thomas Smeenck talks about Hemostemix's portfolio of autologous stem cell therapies that uses patient's own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward with its promising therapies.

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

## About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

**On October 21, 2019**, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To learn more about Hemostemix Inc., [click here](#).

***Disclaimer:*** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties

that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

# Hemostemix's stem cell therapy pursues 'Your Fountain of Youth'

written by InvestorNews | August 11, 2023

What's a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood flow) and tissue damage, and potentially [improve the quality of life](#)? It would be hard to put a price on such a company if they could successfully commercialize or license their product or technology.

Today's company, [Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0), is having remarkable success, yet due to its early stage has a market cap of only [C\\$19 million](#). That company is developing methods that use our own bodies' stem cells to heal certain diseases. The key diseases of focus for now are those revolving around ischemia, such as heart disease, stroke, and diabetic vascular disease and its complications such as limb loss. Over the next year, there will also be a lot of work done on nerve cell regeneration.

[Hemostemix Inc.](#) is developing 'stem cell therapy' for the treatment of ischemic disease and several other diseases. Hemostemix [owns 91 patents](#) across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

Results to date have been outstanding, as shown in the image below.

**Hemostemix summary of the business and ACP-01**

ACP-01 is Hemostemix's pioneering first stem cell treatment called angiogenic cell precursor ("ACP"). Hemostemix [states](#): "ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted **healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.**"

*Note: Bold emphasis by the author.*

With such stunning success, it is little wonder that Hemostemix is very keen to protect their intellectual property.

On February 14, 2022 Hemostemix [announced](#) that they had "been granted International Trademark Registration No. 1624069 for **Your Fountain of Youth**, a registration that is valid for a period of 10 years." Hemostemix further [announced](#) on March 23, 2022 that it had resolved outstanding litigation with a settlement agreement that requires the other parties to return all data and intellectual property in relation to ACP-01 in their possession to Hemostemix.

This is a great outcome for Hemostemix and good news to investors, as the Company believes their ACP-01 intellectual property is incredibly valuable.

Hemostemix has previously published numerous other studies proving the benefit of ACP-01, notably in the treatment of ischemia in various parts of the body. Some examples include [improving ischemic cardiomyopathy patients](#) and [limb ischemia](#)



[patients](#).

*Note: NCP stands for Nerve Cell Precursor. CCP stands for Cardiac Cell Precursor. These are cultivated from the patient's own stem cells using Hemostemix's patented technologies.*

### **What's next for Hemostemix?**

Apart from further studies, Hemostemix is now looking towards automating production, partnering and commercialization. The goal of improving stem cell production will help lower costs and potentially expand the business. Hemostemix also intends to advance their business development plans including possible licensing of their technology.

To help fund the above, Hemostemix recently announced a [\\$2,750,000 Convertible Debenture offering](#).

### **Closing remarks**

Hemostemix's longer-term goal is to support a higher quality of life for all of us, a veritable "fountain of youth", where we could boost our health yearly with our own stem cells to help repair our bodies.

Hemostemix trades on a market cap of [C\\$19 million](#). Risk remains high due to the early stage, however there is truly blue sky potential if the Company can successfully license or commercialize their products in future years.

---

# Thomas Smeenck on Hemostemix products for Your Fountain of Youth

written by InvestorNews | August 11, 2023

In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenck, Co-Founder, President and CEO of [Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF) about Hemostemix's recent "blockbuster" [news release](#) on collaborating with world famous [Dr. James Shapiro](#) to Treat Type 1 Diabetes and about trademarking "Your Fountain of Youth".

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Thomas Smeenck said that Dr. James Shapiro is well known and respected for creating the Edmonton Protocol for the treatment of Type 1 Diabetes. Thomas went on to provide an update on Hemostemix's technology platform that uses stem cells from a patient's own blood to treat the heart-damage following a heart attack. Providing an update on Hemostemix's recently closed oversubscribed private placement, he went on to explain how Hemostemix has found a "Fountain of Youth."

To watch the full interview, [click here](#).

## About Hemostemix Inc.

Hemostemix is a publicly traded autologous (utilizing the patient's own stem cells) stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic

Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

**On October 21, 2019,** the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To learn more about Hemostemix Inc., [click here](#).

***Disclaimer:*** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of

the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).